Pierre Fabre is making Spain the starting point for Même's international expansion. The dermocosmetics brand will arrive in Spanish pharmacies and El Corte Inglés in October, with products for oncology patients and people with sensitive or reactive skin.
The Spanish launch includes 74 products in six categories, covering facial and body care. The range also includes nail polish and makeup, and is designed for changes that can affect the skin, with effects also seen in hair and nails.
Juliette Couturier and Judith Levy founded Même in 2016 after a personal experience. Pierre Fabre became its majority shareholder in 2023, while leaving the brand with its own identity and entrepreneurial spirit.
Pierre Fabre is bringing its research and development capacity to the expansion. Oncology and dermatology are among the group's basic therapeutic areas, linking Même to the medical fields connected to its target customers. The group's launch materials describe a strategy rooted in medical expertise as well as beauty retail.
The launch also challenges a narrow view of oncology skincare. Même is aimed at cancer patients, but its products are also intended for men. Men account for 47% of cancers diagnosed in Spain and can experience side effects affecting the skin, as well as hair and nails, just like women. The brand is so not limited to a women's beauty offer.
Safety is central to the range. Its products are made with ingredients that are 98% natural in origin and have been tested in hospitals with oncologists and patients. A line of sun protection products is expected to join the range soon.
The distribution plan gives the brand national reach from the start. Pharmacies place the products close to healthcare advice, while El Corte Inglés adds a major retail channel. Together, the two routes connect Même's medical positioning with everyday access to products for the face and body, alongside nail and makeup items.
Pierre Fabre and Même are using the Spanish launch to pursue a broader commercial and therapeutic goal: creating an oncology cosmetics category. The group says it wants to lead that category and become a reference for oncology patients, while also serving people with sensitive and reactive skin.
Hospital testing and specialist focus will have to earn practical trust at the point of purchase. The strategy rests on 74 products and pharmacy distribution, backed by hospital testing and a high natural-ingredient profile; a sun protection line is planned. Spain is more than Même's first foreign market: it is the first test of whether oncology cosmetics can become a distinct category, rather than remain a niche within conventional dermocosmetics.
